The benefit of GLP-1RA in different age groups in the cardiovascular outcome trials. (July 2021)

• Record Type: Journal Article
• Authors: Younes, Ahmed M.; Mishriky, Basem M.; Powell, James R; Cummings, Doyle M
• Is Part Of: Diabetes research and clinical practice. Volume 177(2021)
• Publication Date: 2021-07
• Subjects: Type 2 diabetes -- Older adults -- GLP-1RA -- Cardiovascular outcome trials; Diabetes -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462
• DOI: 10.1016/j.diabres.2021.108878
• Languages: English
• ISSNs: 0168-8227

Abstract

Highlights: There may be hesitancy in prescribing GLP-1RA in older adults. GLP-1RAs were associated with lower incidence of MACE regardless of baseline age. GLP-1RAs should be considered in appropriately selected older adults. Abstract: There may be hesitancy in prescribing GLP-1RA in older adults. On pooling results from the CVOTs comparing GLP-1RA to placebo, there was a significantly lower incidence of MACE favoring GLP-1RA in both younger and older adults. GLP-1RA should be considered in high risk patients regardless of age.